

Thursday 10 October, 09:00 to 16:00
The Hibernia Conference Centre, Dublin Castle

Registration opens at 08:15 **Tea/coffee and pastries on arrival**

Opening

Stakeholder Perspectives on HTA	09.00 to 10.30
National HTA Agency	Prof Michael Barry, Clinical Director NCPE
Healthcare Decision Maker	Niall Redmond, Department of Health
Industry	Shane Ryan, IPHA President
Public/Patient	Neurofibroma Ireland

Panel Discussion

Break	10.30 to 11.00
Plenary Session	11.00 to 12.10
Public policy issues around cancer medicines	Prof Richard Sullivan (Institute of Cancer Policy, King's College London)
Challenges associated with evidence for cancer drugs from a HTA perspective	Dr Mattias Neyt (Belgian Healthcare Knowledge Centre)
NCPE perspective on HTA of cancer medicines and future research	Dr Caroline Walsh, NCPE

Panel Discussion

National & International Perspectives on HTA	12.10 to 13.00
National HTA 2023-2024	Dr Lesley Tilson, NCPE
Challenges in HTA: The perspective of an international HTA consultancy	Suzette Matthijsse, Humanity

Q&A

Lunch	13.00 to 14.00
HTA in Practice:	14.00 to 15.00
Patient Organisation Submissions made to the NCPE	Joan O'Callaghan, NCPE
International/National Horizon Scanning	Dr Roisin Adams, NCPE
Developing an NCPE-adjusted Base Case	Dr Emer Fogarty, NCPE

Q&A

Implementation of the EU HTA Regulation	15.00 to 16.00
The Role of the NCPE Assessor in the JSC subgroup	Dr Niamh Carey, NCPE
Working Towards National Implementation of the EU HTA Regulation	Dr Emer Fogarty, NCPE

Panel Discussion

Closing Remarks **Prof Michael Barry**